NCT01933503View on ClinicalTrials.gov

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Healthy
Interventions
DRUG

OCA 5 mg

DRUG

OCA 10 mg

DRUG

OCA 25 mg

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

Sponsors
All Listed Sponsors
lead

Intercept Pharmaceuticals

INDUSTRY